Jump Financial’s Recursion Pharmaceuticals RXRX Stock Holding History

Jump Financial’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.73M	Buy	889,933 +228,304	+35%	+$882K	0.04%	546
2025 Q4	$2.71M	Buy	661,629 +106,551	+19%	+$528K	0.03%	569
2025 Q3	$2.71M	Sell	555,078 -596,123	-52%	-$3.13M	0.03%	619
2025 Q2	$5.83M	Buy	1,151,201 +558,848	+94%	+$2.75M	0.06%	372
2025 Q1	$3.13M	Buy	592,353 +578,859	+4,290%	+$4.22M	0.04%	449
2024 Q4	$91.2K	Buy	+13,494	New	+$90.7K	﹤0.01%	1548
2023 Q4	–	Sell	-253,464	Closed	-$1.94M	–	2182
2023 Q3	$1.94M	Buy	253,464 +241,615	+2,039%	+$2.41M	0.07%	383
2023 Q2	$88.5K	Sell	11,849 -117,692	-91%	-$823K	﹤0.01%	1671
2023 Q1	$864K	Buy	+129,541	New	+$1.03M	0.04%	659

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Jump Financial's RXRX Position: Q1 2026 in Review

Jump Financial increased its Recursion Pharmaceuticals (RXRX) stake by 35% in Q1 2026, buying an estimated $882K and bringing the position to 889,933 shares worth $2.73M. The position accounts for 0.04% of the portfolio, ranked #546.

Jump Financial first reported a position in RXRX in Q1 2023 and has held it in 9 quarters since. The position peaked at $5.83M in Q2 2025. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Jump Financial held 889,933 shares of Recursion Pharmaceuticals worth $2.73M as of Q1 2026.
Jump Financial bought 228,304 Recursion Pharmaceuticals shares in Q1 2026, an estimated $882K.
Recursion Pharmaceuticals made up 0.04% of Jump Financial's portfolio in Q1 2026, its #546 holding.
Jump Financial first reported a position in Recursion Pharmaceuticals in Q1 2023 and has held it in 9 quarters since.
Jump Financial's Recursion Pharmaceuticals position peaked at $5.83M in Q2 2025.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.